Immunovia realigning Swedish operations with strategic priorities and its focus on the US commercialization of the IMMray™ PanCan-d test
LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world’s first blood test dedicated to the early detection of pancreatic cancer, today announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test. In October 2022, Immunovia announced a research collaboration partnership with the Swiss diagnostic company Proteomedix. The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based